Advertisement

Fishing for ALK with immunohistochemistry may predict response to crizotinib

Abstract

Background. ALK (anaplastic lymphoma kinase) gene rearrangement is a novel oncogenic driver in non-small cell lung cancer (NSCLC) against which a selective inhibitor, namely crizotinib, is effective. Fluorescence in situ hybridization (FISH) is considered the reference method in selecting patients with ALK-positive tumors for treatment with crizotinib.
Case report. We report the case of a 42-year-old non-smoking woman with an advanced pulmonary ALK FISH-negative adenocarcinoma characterized by strong immunohistochemical expression of ALK fusion protein. The patient received targeted therapy with crizotinib in compassionate use and experienced a ong-lasting clinical response.
Conclusion. FISH testing should not be considered the only method to select patients for therapy with ALK inhibitors and the use of multiple ALK-detecting techniques could be helpful in screening ALK-positive patients more appropriately.

Tumori 2013; 99(5): e229 - e232

Article Type: CASE REPORT

DOI:10.1700/1377.15321

Authors

Mario Bavieri, Marcello Tiseo, Sylvie Lantuejoul, Anne McLeer-Florin, Anna Lasagni, Riccardo Fantini, Giulio Rossi

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Bavieri, Mario [PubMed] [Google Scholar]
    Department of Oncology and Hematology, Respiratory Disease Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
  • Tiseo, Marcello [PubMed] [Google Scholar]
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
  • Lantuejoul, Sylvie [PubMed] [Google Scholar]
    Département d’Anatomie et Cytologie Pathologiques et Plateforme Hospitaliere de Genetique Moleculaire des Cancers, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire A Michallon, Grenoble, France, Italy
  • McLeer-Florin, Anne [PubMed] [Google Scholar]
    Département d’Anatomie et Cytologie Pathologiques et Plateforme Hospitaliere de Genetique Moleculaire des Cancers, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire A Michallon, Grenoble, France, Italy
  • Lasagni, Anna [PubMed] [Google Scholar]
    Department of Oncology and Hematology, Respiratory Disease Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
  • Fantini, Riccardo [PubMed] [Google Scholar]
    Department of Oncology and Hematology, Respiratory Disease Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
  • Rossi, Giulio [PubMed] [Google Scholar]
    Unità Operativa di Anatomia Patologica, Azienda Arcispedale Santa Maria Nuova/Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.